Sponsors (2)
The bill expands and standardizes access to fentanyl/xylazine test strips and training—likely reducing overdoses and strengthening public‑health response—while increasing federal/local costs, imposing implementation and compliance burdens, and risking narrower regulatory limits that could restrict some community harm‑reduction options.
First responders (police, firefighters, EMS) and frontline clinicians (emergency departments, hospitals) will receive training, tools, and clinical decision support to detect fentanyl and xylazine on‑scene and in clinical settings, improving immediate overdose detection and response.
People who use drugs and patients at risk of accidental exposure will gain wider access to rapid single‑use test strips and clearer standards, helping them identify fentanyl, xylazine, and other adulterants and reducing the risk of fatal overdoses.
Community organizations and social‑service providers will get resources and training to distribute and support use of test strips, increasing harm‑reduction access for vulnerable populations.
Taxpayers and federal/local budgets will face higher costs to buy test strips, run trainings, conduct studies, and staff development of frameworks, increasing public spending.
Local jurisdictions, employers, and federal agencies will incur administrative and staff burdens to implement trainings, run programs, and carry out the mandated study and framework development.
Community harm‑reduction programs and people who use drugs could face reduced access if federal frameworks emphasize clinical diagnostic use or the statutory definition narrows authorized technologies, restricting simpler, community‑oriented test strip distribution.
Based on analysis of 5 sections of legislative text.
Directs HHS to create regulatory frameworks for fentanyl/xylazine test strips, requires training/resources for responders, and mandates a study/report on drug‑checking impacts.
Requires HHS to create research and marketing frameworks for rapid test strips that detect fentanyl, xylazine, and other dangerous substances; adds training and resource responsibilities so first responders and other community sectors can carry and facilitate access to test strips; and directs HHS to study how drug‑checking supplies affect overdoses and treatment engagement and report results to Congress within two years. The bill also defines "test strip" to include single‑use, rapid diagnostics for drug adulterants or substances in human specimens.
Official title: To require research with respect to fentanyl and xylazine test strips, to authorize the use of grant funds for such test strips, and for other purposes.
Introduced February 25, 2025 by Jasmine Crockett · Last progress February 25, 2025